Bian Shan, Repic Marko, Guo Zhenming, Kavirayani Anoop, Burkard Thomas, Bagley Joshua A, Krauditsch Christian, Knoblich Jürgen A
Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
MC Toxicology Consulting, Vienna, Austria.
Nat Methods. 2018 Sep;15(9):748. doi: 10.1038/s41592-018-0118-8.
In the originally published paper, the "before" image for the afatinib condition in Fig. 6c was incorrect. Instead of an image displaying a GBM-3 neoplastic organoid before afatinib treatment, this panel showed an image from the GBM-2 control (DMSO) group before treatment. This error has now been corrected in the HTML and PDF versions of the article; the "before, afatinib" panel in Fig. 6c now shows a representative image from the indicated experiment. The color of all error bars in Fig. 6 has also been changed to black, for consistency. All statistical analysis and all conclusions presented in the article are unaffected by this error. Nevertheless, we apologize for the mistake.
在最初发表的论文中,图6c中阿法替尼条件下的“治疗前”图像有误。该图展示的不是阿法替尼治疗前的胶质母细胞瘤-3肿瘤类器官图像,而是治疗前GBM-2对照组(二甲基亚砜)的图像。此错误现已在文章的HTML和PDF版本中更正;图6c中“阿法替尼治疗前”板块现在显示的是指定实验的代表性图像。为保持一致,图6中所有误差线的颜色也已更改为黑色。文章中呈现的所有统计分析和所有结论均不受此错误影响。尽管如此,我们仍为这一错误表示歉意。